Nevro to Present at Truist Securities MedTech Conference
REDWOOD CITY, Calif., June 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.
Here's Why Nevro Corp. (NVRO) Shares Detracted From Performance
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
Nevro Grantd Inducement Restricted Stk Unit Awards Covering 59,460 Common Shrs to 26 New Non-Executive Employees >NVRO
Nevro Grantd Inducement Restricted Stk Unit Awards Covering 59,460 Common Shrs to 26 New Non-Executive Employees >NVRO
Citi Downgrades Nevro(NVRO.US) to Sell Rating, Cuts Target Price to $9
Citi analyst Joanne Wuensch downgrades $Nevro(NVRO.US)$ to a sell rating, and adjusts the target price from $16 to $9.According to TipRanks data, the analyst has a success rate of 62.2% and a total av
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Express News | Nevro Corp : Citigroup Cuts Target Price to $9 From $13.5
Express News | Nevro Corp : Citigroup Cuts to Sell From Neutral
Engaged Capital's Q1 Moves: Adds Envestnet, Trims Shake Shack, Others
Truist Financial Remains a Hold on Nevro Corp (NVRO)
Insider Traders Lose US$98k As Nevro Drops
Insiders who acquired US$171.6k worth of Nevro Corp.'s (NYSE:NVRO) stock at an average price of US$22.88 in the past 12 months may be dismayed by the recent 13% price decline. This is not good as ins
Nevro Promotes New Chief Operating Officer From Within
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Nevro Corp Announces Christoforou as New COO With Incentives
Express News | Nevro Corp : Truist Securities Cuts Target Price to $11 From $14
Assessing Nevro: Insights From 9 Financial Analysts
9 analysts have shared their evaluations of Nevro (NYSE:NVRO) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent r
Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained
Nevro (NVRO) has an average rating of hold and price targets ranging from $10 to $40, according to analysts polled by Capital IQ. Price: 10.35, Change: -1.18, Percent Change: -10.23
Nevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call Transcript
Nevro Price Target Cut to $11.00/Share From $17.00 by Canaccord Genuity
Nevro Price Target Cut to $11.00/Share From $17.00 by Canaccord Genuity
No Data